Sökning: WFRF:(Lindner Peter)
> (2000-2009) >
Combined treatment ...
Combined treatment with histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma
-
Lindner, P. (författare)
-
Rizell, Magnus, 1963 (författare)
-
- Mattsson, Jan (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för de kirurgiska disciplinerna, Avdelningen för kirurgi,Institute of Surgical Sciences, Department of Surgery
-
visa fler...
-
- Hellstrand, Kristoffer, 1956 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för laboratoriemedicin, Avdelningen för klinisk virologi,Institute of Laboratory Medicine, Dept of Clinical Virology
-
- Naredi, Peter, 1955 (författare)
- Umeå universitet,Kirurgi
-
visa färre...
-
(creator_code:org_t)
- 2004
- 2004
- Engelska.
-
Ingår i: Anticancer Res. - 0250-7005. ; 24:3b, s. 1837-42
- Relaterad länk:
-
http://www.ncbi.nlm....
-
visa fler...
-
https://gup.ub.gu.se...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- BACKGROUND: Histamine inhibits phagocyte-derived production of reactive oxygen species and improves the anti-tumour efficiency of interleukin-2 (IL-2) and interferon-alpha (IFN-alpha) in vitro and in tumour-bearing animals. PATIENTS AND METHODS: In a phase-II study, twenty-seven patients with stage IV melanoma received subcutanous injections of histamine dihydrochloride (histamine) 1.0 mg and IL-2 2.4 MIU/m2 twice daily (BID) days 1-5 and 8-12. IFN-alpha 3 MIU once daily was administered throughout a cycle (days 1-28; n=14). Alternatively, bolus doses of IL-2 10 MIU/m2 BID days 1 and 2 and histamine days 1-28 (n=13) were administered. The aim was to study efficiency (survival and tumour response), toxicity and histamine pharmacokinetics. RESULTS: The median survival time was 11.3 (2.5-45) months. One patient achieved a complete response and 3 patients had partial responses. The compounds were safely self-administered with low toxicity. Plasma histamine concentrations significantly increased after an injection of histamine over 10 minutes (3 +/- 1 vs. 63 +/- 27 nmol/l). CONCLUSION: Histamine, IL-2 and IFN-alpha treatment is safe, well-tolerated and tumour responses were observed. The putative efficiency of histamine as an adjunct to cytokine therapy in metastatic melanoma needs to be confirmed in later randomized trials.
Nyckelord
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols/adverse effects/ therapeutic use
- Female
- Histamine/administration & dosage/adverse effects/blood/pharmacokinetics
- Humans
- Immunotherapy/ methods
- Interferon Alfa-2b/administration & dosage/adverse effects
- Interleukin-2/administration & dosage/adverse effects
- Male
- Melanoma/blood/secondary/ therapy
- Middle Aged
- Adult
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas